Missing: Ablation Frontiers's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Ablation Frontiers's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest Ablation Frontiers News
Oct 26, 2011
October 26, 2011 8:09am Comments Share: A report from Morgan Keegan reiterates its Market Perform rating and $38 price target on Medtronic (NYSE: MDT ). The report states, “Medtronic's Ablation Frontiers system for ablating persistent and long-standing persistent atrial fibrillation ( AF ) will likely not be recommended for approval by the FDA Advisory Panel. We believe the chance could be as low as 30% that Medtronic… will be successful. " MDT closed yesterday at $33.73. © 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ablation Frontiers Frequently Asked Questions (FAQ)
When was Ablation Frontiers founded?
Ablation Frontiers was founded in 2004.
Where is Ablation Frontiers's headquarters?
Ablation Frontiers's headquarters is located at 6354 Corte Del Abeto, Carlsbad.
What is Ablation Frontiers's latest funding round?
Ablation Frontiers's latest funding round is Acquired.
How much did Ablation Frontiers raise?
Ablation Frontiers raised a total of $40.3M.
Who are the investors of Ablation Frontiers?
Investors of Ablation Frontiers include Medtronic, Versant Ventures, Pequot Venture Capital, Aberdare Ventures, Affinity Ventures and 6 more.
Who are Ablation Frontiers's competitors?
Competitors of Ablation Frontiers include Cardiac Dimensions, Cyberheart, NeuWave Medical, MiCardia, OrSense and 12 more.
Compare Ablation Frontiers to Competitors
NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. The company was founded in 2007 and is based in Minneapolis, Minnesota.
InnerPulse develops minimally invasive devices for cardiac rhythm management
Abla-Tx Inc is a private company founded in 2005 to develop a software based algorithm to monitor thermal ablation of tumors. Abla-Tx has been formed to help guide minimally invasive methods for the treatment of all malignant and benign solid tumors. A patented method of monitoring temperature during thermal ablation in conjunction with CT and digital x-ray imaging will be developed and commercialized. Regulatory approval will be sought to allow the sale of a software based thermal mapping system that will be used in conjunction with CT and planar x-ray imaging systems.
OrSense provides non-invasive monitoring of various blood constituencies.
Varix Medical Corporation, located in Sunnyvale, Calif., is a medical device company focused on developing products for the minimally invasive treatment of chronic venous insufficiency, commonly referred to as "varicose veins." For patients with advanced stages of varicose veins, laser- and RF-based (radiofrequency) treatments have been developed, but each device has deficiencies making them less-than-optimal solutions. Varix Medical's platform technology will enable physicians to efficiently and effectively treat more types of diseased veins than is currently possible when using either laser or RF devices. Additional treatable vessels include tortuous sub-truncal vessels and other visible smaller varicose veins. The Varix platform employs a vapor-based endovenous ablation system that will consist of a disposable catheter, a catheter introducer or delivery system, and a reusable vapor generator. RCT and Coronis Medical Ventures LLC., formed Varix in August 2007 and acquired the technology under license from Tsunami MedTech LLC. Coronis and RCT have been the primary in investors in Varix.
Angel Medical Systems develops the AngelMed Guardian system, an implantable cardiac monitoring and alerting system that is designed to warn cardiac patients of potentially life-threatening heart conditions. The AngelMed Guardian System heart monitor is designed to track changes in the heart's electrical signal from a standard pacemaker lead, identify the signature of acute thrombotic occlusions when they occur, and then alert the patient directly to seek medical attention. The device is being studied in high risk heart patients who do not qualify for an ICD, but who have had a STEMI, NSTEMI or unstable angina in their recent past. The company was founded in 2001 and is based in Eatontown, New Jersey.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.